Lanadelumab vs placebo or active control
Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 64 participantsLow